Skip to content Skip to navigation
University of Warwick
  • Study
  • |
  • Research
  • |
  • Business
  • |
  • Alumni
  • |
  • News
  • |
  • About

University of Warwick
Publications service & WRAP

Highlight your research

  • WRAP
    • Home
    • Search WRAP
    • Browse by Warwick Author
    • Browse WRAP by Year
    • Browse WRAP by Subject
    • Browse WRAP by Department
    • Browse WRAP by Funder
    • Browse Theses by Department
  • Publications Service
    • Home
    • Search Publications Service
    • Browse by Warwick Author
    • Browse Publications service by Year
    • Browse Publications service by Subject
    • Browse Publications service by Department
    • Browse Publications service by Funder
  • Help & Advice
University of Warwick

The Library

  • Login
  • Admin

An international longitudinal registry of patients with atrial fibrillation at risk of stroke (GARFIELD) : the UK protocol

Tools
- Tools
+ Tools

UK GARFIELD Investigators, GARFIELD Steering Committee (Including: Apenteng, Patricia N., Murray, Ellen T., Holder, Roger L., Hobbs, Richard F. D. and Fitzmaurice, David A.). (2013) An international longitudinal registry of patients with atrial fibrillation at risk of stroke (GARFIELD) : the UK protocol. BMC Cardiovascular Disorders, 13 . 31. doi:https://doi.org/10.1186/1471-2261-13-31

[img]
Preview
PDF
WRAP-An-international-patients-atrial-fibrillation-stroke-GARFIELD-UK-2020.pdf - Published Version - Requires a PDF viewer.
Available under License Creative Commons Attribution 4.0.

Download (356Kb) | Preview
Official URL: https://doi.org/10.1186/1471-2261-13-31

Request Changes to record.

Abstract

Background
Atrial fibrillation (AF) is an independent risk factor for stroke and a significant predictor of mortality. Evidence-based guidelines for stroke prevention in AF recommend antithrombotic therapy corresponding to the risk of stroke. In practice, many patients with AF do not receive the appropriate antithrombotic therapy and are left either unprotected or inadequately protected against stroke. The purpose of the Global Anticoagulant Registry in the FIELD (GARFIELD) is to determine the real-life management and outcomes of patients newly diagnosed with non-valvular AF.

Methods/design
GARFIELD is an observational, international registry of newly diagnosed AF patients with at least one additional investigator-defined risk factor for stroke. The aim is to enrol 55,000 patients at more than 1000 centres in 50 countries worldwide. Enrolment will take place in five independent, sequential, prospective cohorts; the first cohort includes a retrospective validation cohort. Each cohort will be followed up for 2 years. The UK stands to be a significant contributor to GARFIELD, aiming to enrol 4,582 patients, and reflecting the care environment in which patients with AF are managed. The UK protocol will also focus on better understanding the validity of the two main stroke risk scores (CHADS2 and CHA2DS2VASC) and the HAS-BLED bleeding risk score, in the context of a diverse patient population.

Discussion
The GARFIELD registry will describe how therapeutic strategies, patient care, and clinical outcomes evolve over time. This study will provide UK-specific comprehensive data that will allow a range of evaluations both at a national level and in relation to global data and contribute to a better understanding of AF management in the UK.

Item Type: Journal Article
Subjects: Q Science > QP Physiology
R Medicine > RC Internal medicine
R Medicine > RM Therapeutics. Pharmacology
Divisions: Faculty of Medicine > Warwick Medical School > Health Sciences
Faculty of Medicine > Warwick Medical School
Library of Congress Subject Headings (LCSH): Anticoagulants (Medicine) , Atrial fibrillation , Cerebrovascular disease , Cerebrovascular disease -- Patients , Vitamin K
Journal or Publication Title: BMC Cardiovascular Disorders
Publisher: BioMed Central Ltd.
ISSN: 1471-2261
Official Date: 23 April 2013
Dates:
DateEvent
23 April 2013Published
18 April 2013Accepted
Date of first compliant deposit: 8 October 2020
Volume: 13
Article Number: 31
DOI: https://doi.org/10.1186/1471-2261-13-31
Status: Peer Reviewed
Publication Status: Published
Access rights to Published version: Open Access
RIOXX Funder/Project Grant:
Project/Grant IDRIOXX Funder NameFunder ID
UNSPECIFIEDThrombosis Research Institutehttps://www.tri-london.ac.uk/
UNSPECIFIEDBayer Schering Pharma AG Berlinhttp://viaf.org/viaf/168473073
Open Access Version:
  • Publisher

Request changes or add full text files to a record

Repository staff actions (login required)

View Item View Item

Downloads

Downloads per month over past year

View more statistics

twitter

Email us: wrap@warwick.ac.uk
Contact Details
About Us